MX2020005816A - Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados. - Google Patents

Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados.

Info

Publication number
MX2020005816A
MX2020005816A MX2020005816A MX2020005816A MX2020005816A MX 2020005816 A MX2020005816 A MX 2020005816A MX 2020005816 A MX2020005816 A MX 2020005816A MX 2020005816 A MX2020005816 A MX 2020005816A MX 2020005816 A MX2020005816 A MX 2020005816A
Authority
MX
Mexico
Prior art keywords
milling process
step milling
preparing micronized
paliperidone esters
preparing
Prior art date
Application number
MX2020005816A
Other languages
English (en)
Inventor
Baohua Yue
Williams Sanders
Demin Liu
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2020005816A publication Critical patent/MX2020005816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/16—Mills in which a fixed container houses stirring means tumbling the charge
    • B02C17/168—Mills in which a fixed container houses stirring means tumbling the charge with a basket media milling device arranged in or on the container, involving therein a circulatory flow of the material to be milled

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas que comprenden al menos un agente humectante, al menos un excipiente, al menos un amortiguador, al menos un modificador del pH y al menos un ingrediente farmacéutico activo. Métodos para preparar las composiciones farmacéuticas en los que se muele el ingrediente farmacéutico activo para proporcionar una distribución del tamaño de partícula mediante el uso de un proceso de molienda de una sola etapa.
MX2020005816A 2017-12-14 2018-12-13 Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados. MX2020005816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598827P 2017-12-14 2017-12-14
PCT/US2018/065443 WO2019118722A1 (en) 2017-12-14 2018-12-13 One step milling process for preparing micronized paliperidone esters

Publications (1)

Publication Number Publication Date
MX2020005816A true MX2020005816A (es) 2020-08-20

Family

ID=66815477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005816A MX2020005816A (es) 2017-12-14 2018-12-13 Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados.

Country Status (8)

Country Link
US (1) US20190183896A1 (es)
EP (1) EP3723760A4 (es)
JP (1) JP2021506757A (es)
AU (1) AU2018383636B2 (es)
BR (1) BR112020011614A2 (es)
CA (1) CA3084002A1 (es)
MX (1) MX2020005816A (es)
WO (1) WO2019118722A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
CN110279659A (zh) * 2019-07-08 2019-09-27 华裕(无锡)制药有限公司 棕榈酸帕利哌酮制剂及其制备方法
KR20230116836A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
US11324751B1 (en) * 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
DK4025188T3 (da) * 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
US20230085549A1 (en) * 2021-08-30 2023-03-16 Janssen Pharmaceutica Nv Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994041A (en) * 1985-04-06 1999-11-30 Eastman Kodak Company Process for buffering concentrated aqueous slurries
US5902711A (en) * 1997-06-25 1999-05-11 Eastman Kodak Company Method to media mill particles using crosslinked polymer media and organic solvent
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2413330A1 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
ES2893973T3 (es) * 2016-02-17 2022-02-10 Alkermes Pharma Ireland Ltd Composiciones de múltiples profármacos de aripiprazol
CN106137985B (zh) * 2016-08-04 2019-03-08 齐鲁制药有限公司 一种稳定的棕榈酸帕利哌酮长效制剂

Also Published As

Publication number Publication date
WO2019118722A1 (en) 2019-06-20
AU2018383636A1 (en) 2020-06-18
AU2018383636B2 (en) 2024-01-18
CA3084002A1 (en) 2019-06-20
EP3723760A1 (en) 2020-10-21
US20190183896A1 (en) 2019-06-20
JP2021506757A (ja) 2021-02-22
BR112020011614A2 (pt) 2020-12-08
EP3723760A4 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
MX2020005816A (es) Proceso de molienda de una etapa para preparar esteres de paliperidona micronizados.
PH12017500146A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
NZ756231A (en) A novel isoindoline derivative, a pharmaceutical composition and use thereof
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
MX2018000421A (es) Composiciones de retinoides topicos.
NZ712350A (en) Abiraterone acetate formulation
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2016011841A (es) Composiciones topicas de corticosteroides.
IN2013MU03583A (es)
MX2015011770A (es) Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2020005575A (es) Composiciones y metodos de taxano oral de alta resistencia.
NZ767710A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
IN2013MU01177A (es)
MX2023000348A (es) Composicion que contiene ciclodextrina y busulfan.
MX2017001869A (es) Formas cristalinas de un modulador de receptor de estrogeno.
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين